An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration
Latest Information Update: 15 Sep 2026
At a glance
- Drugs VRT-106 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Guangzhou Virotech Pharmaceutical
Most Recent Events
- 10 Sep 2026 Planned End Date changed from 1 Mar 2027 to 1 Mar 2029.
- 10 Sep 2026 Planned primary completion date changed from 30 Dec 2025 to 30 Dec 2028.
- 18 Jul 2025 Status changed from not yet recruiting to recruiting.